CRBP
Price
$4.92
Change
-$0.28 (-5.38%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
60.18M
SKYE
Price
$1.41
Change
-$0.02 (-1.40%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
43.98M
Ad is loading...

CRBP vs SKYE

Header iconCRBP vs SKYE Comparison
Open Charts CRBP vs SKYEBanner chart's image
Corbus Pharmaceuticals Holdings
Price$4.92
Change-$0.28 (-5.38%)
Volume$1.94K
Capitalization60.18M
Skye Bioscience
Price$1.41
Change-$0.02 (-1.40%)
Volume$800
Capitalization43.98M
CRBP vs SKYE Comparison Chart
Loading...
CRBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SKYE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRBP vs. SKYE commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRBP is a Hold and SKYE is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (CRBP: $4.92 vs. SKYE: $1.42)
Brand notoriety: CRBP and SKYE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRBP: 90% vs. SKYE: 129%
Market capitalization -- CRBP: $60.18M vs. SKYE: $43.98M
CRBP [@Biotechnology] is valued at $60.18M. SKYE’s [@Biotechnology] market capitalization is $43.98M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRBP’s FA Score shows that 0 FA rating(s) are green whileSKYE’s FA Score has 1 green FA rating(s).

  • CRBP’s FA Score: 0 green, 5 red.
  • SKYE’s FA Score: 1 green, 4 red.
According to our system of comparison, SKYE is a better buy in the long-term than CRBP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRBP’s TA Score shows that 5 TA indicator(s) are bullish while SKYE’s TA Score has 4 bullish TA indicator(s).

  • CRBP’s TA Score: 5 bullish, 3 bearish.
  • SKYE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, CRBP is a better buy in the short-term than SKYE.

Price Growth

CRBP (@Biotechnology) experienced а -15.03% price change this week, while SKYE (@Biotechnology) price change was -33.02% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.91%. For the same industry, the average monthly price growth was -11.19%, and the average quarterly price growth was -14.86%.

Reported Earning Dates

CRBP is expected to report earnings on May 11, 2023.

SKYE is expected to report earnings on Nov 29, 2023.

Industries' Descriptions

@Biotechnology (-8.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRBP($60.2M) has a higher market cap than SKYE($44M). SKYE YTD gains are higher at: -49.823 vs. CRBP (-55.932). SKYE has higher annual earnings (EBITDA): -19.64M vs. CRBP (-37.75M). CRBP has more cash in the bank: 149M vs. SKYE (67.4M). SKYE has less debt than CRBP: SKYE (191K) vs CRBP (3.24M). CRBP (0) and SKYE (0) have equivalent revenues.
CRBPSKYECRBP / SKYE
Capitalization60.2M44M137%
EBITDA-37.75M-19.64M192%
Gain YTD-55.932-49.823112%
P/E RatioN/A3.57-
Revenue00-
Total Cash149M67.4M221%
Total Debt3.24M191K1,696%
FUNDAMENTALS RATINGS
CRBP vs SKYE: Fundamental Ratings
CRBP
SKYE
OUTLOOK RATING
1..100
6360
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
32
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
9797
P/E GROWTH RATING
1..100
10097
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SKYE's Valuation (32) in the null industry is in the same range as CRBP (54) in the Biotechnology industry. This means that SKYE’s stock grew similarly to CRBP’s over the last 12 months.

SKYE's Profit vs Risk Rating (100) in the null industry is in the same range as CRBP (100) in the Biotechnology industry. This means that SKYE’s stock grew similarly to CRBP’s over the last 12 months.

SKYE's SMR Rating (97) in the null industry is in the same range as CRBP (98) in the Biotechnology industry. This means that SKYE’s stock grew similarly to CRBP’s over the last 12 months.

SKYE's Price Growth Rating (97) in the null industry is in the same range as CRBP (97) in the Biotechnology industry. This means that SKYE’s stock grew similarly to CRBP’s over the last 12 months.

SKYE's P/E Growth Rating (97) in the null industry is in the same range as CRBP (100) in the Biotechnology industry. This means that SKYE’s stock grew similarly to CRBP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRBPSKYE
RSI
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
89%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
84%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 10 days ago
81%
Bullish Trend 10 days ago
86%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
78%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
CRBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SKYE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NWHQX27.93N/A
N/A
Nationwide Bailard Tech & Sci M
GLVYX79.00N/A
N/A
Invesco Global Focus Y
VGRIX79.29N/A
N/A
JPMorgan US Value A
CBSAX21.79N/A
N/A
Columbia Select Mid Cap Growth Fund A
AZMCX16.28N/A
N/A
Virtus NFJ Emerging Markets Value C

CRBP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRBP has been loosely correlated with SKYE. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if CRBP jumps, then SKYE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRBP
1D Price
Change %
CRBP100%
+3.38%
SKYE - CRBP
41%
Loosely correlated
+2.14%
APLS - CRBP
36%
Loosely correlated
+1.41%
FBIO - CRBP
36%
Loosely correlated
+4.55%
STOK - CRBP
29%
Poorly correlated
+5.94%
PMCB - CRBP
28%
Poorly correlated
+0.78%
More

SKYE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SKYE has been loosely correlated with CRBP. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if SKYE jumps, then CRBP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SKYE
1D Price
Change %
SKYE100%
-0.70%
CRBP - SKYE
45%
Loosely correlated
-5.38%
JANX - SKYE
40%
Loosely correlated
-4.46%
VKTX - SKYE
34%
Loosely correlated
-5.69%
DNLI - SKYE
28%
Poorly correlated
-6.91%
PGEN - SKYE
27%
Poorly correlated
-9.80%
More